T1	intervention 14 23	letrozole
T2	control 38 47	tamoxifen
T3	total-participants 627 664	Four thousand nine hundred twenty-two
T6	outcome-Measure 961 988	Disease-free survival (DFS)
T7	iv-bin-abs 1069 1072	352
T8	outcome 1073 1083	DFS events
T9	intervention-participants 1090 1095	2,463
T10	cv-bin-abs 1126 1129	418
T11	control-participants 1143 1148	2,459
T12	outcome 1215 1231	risk of an event
T4	eligibility 678 741	postmenopausal women with receptor-positive early breast cancer
T5	outcome 1425 1446	thromboembolic events
T13	outcome 1448 1469	endometrial pathology
T14	outcome 1471 1482	hot flashes
T15	outcome 1484 1496	night sweats
T17	outcome 1502 1518	vaginal bleeding
T16	outcome 1559 1573	bone fractures
T18	outcome 1575 1585	arthralgia
T19	outcome 1587 1617	low-grade hypercholesterolemia
T20	outcome 1623 1644	cardiovascular events
T21	outcome 1337 1351	Adverse events
